Skip to main content
Consumer Siteexternal-link-icon
Tylenol Pro Logo

Comorbidities and Analgesic Choice

TYLENOL® is an appropriate analgesic choice for many patients, including those with certain comorbid conditions

Medical professional discussing comorbidities and analgesic choice with a patient.

54%* of patients may be at risk for adverse events if their comorbidities are not considered in pain reliever recommendations.1
Consider TYLENOL®:  

  • Appropriate for a wide range of patients, including those on aspirin heart therapy and those with a history of gastrointestinal (GI) problems or kidney dysfunction2-7 
  • Does not increase the risk of heart attack, heart failure, or stroke the way NSAIDs such as ibuprofen or naproxen sodium can8 
  • Does not irritate the stomach the way aspirin, naproxen sodium, or ibuprofen can3-6 
Graphic depicting a blood vessel with red and white blood cells.

Cardiovascular Disease

See CVD considerations
Graphic depicting the gastrointestinal tract.

Gastrointestinal Risks

See GI considerations

References:

1. Data on file. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Cross Condition Report. Fort Washington, PA; 2011.
2. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817.
3. Hoftiezer JW, O’Laughlin JC, Ivey KJ. Effects of 24 hours of aspirin, Bufferin, paracetamol and placebo on normal human gastroduodenal mucosa. Gut. 1982;23(8):692-697.
4. Blot WJ, McLaughlin JK. Over the counter non-steroidal anti-inflammatory drugs and risk of gastrointestinal bleeding.  J Epidemiol Biostat. 2000;5(2):137-142.
5. Naproxen. MedlinePlus. Updated March 15, 2022. Accessed March 19, 2023. https://www.nlm.nih.gov/ medlineplus/druginfo/meds/a681029.html
6. Frech EJ, Go MF. Treatment and chemoprevention of NSAID-associated gastrointestinal complications. Ther Clin Risk Manag. 2009;5(1):65-73.
7. Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kidney Dis. 1996;27(1):162-165.
8. FDA strengthens warning of heart attack and stroke risk for non-steroidal antiinflammatory drugs. US Food and Drug Administration. June 9, 2015. Accessed March 20, 2023. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory#:~:text=Safety%20Announcement,a%20heart%20attack%20or%20stroke

*Percentage of consumers age 45+ who have high blood pressure, kidney disease, or are taking low-dose aspirin for heart health and, thus, may not be appropriate to use NSAIDs.